ArticleEJNMMI radiopharmacy and chemistry2020
Article in EJNMMI radiopharmacy and chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Emerging Theranostic Radiometals (Pharmaceuticals (Basel, Switzerland) · 2026Review
- A true theranostic pair -European journal of nuclear medicine and molecular imaging · 2026Article
- Evaluation of Bifunctional, PSMA-Targeted Triazamacrocycle-Picolinates Compatible with theJournal of medicinal chemistry · 2025Article
- Sc(III) Complexes of Pyclen Derivative Ligands as Probes for Hypoxia: Synthesis, Chemical Characterization,Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Preclinical evaluation of [EJNMMI radiopharmacy and chemistry · 2025Article
- Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy.Materials today. Bio · 2025Article
- Impact of cell geometry, cellular uptake region, and tumour morphology onEJNMMI physics · 2024Article
- Activity quantification and dosimetry in radiopharmaceutical therapy with reference toFrontiers in nuclear medicine · 2024Review
- Scandium Radioisotopes-Toward New Targets and Imaging Modalities.Molecules (Basel, Switzerland) · 2023Review
- Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling.RSC medicinal chemistry · 2023Review
- Modern Developments in Bifunctional Chelator Design for Gallium Radiopharmaceuticals.Molecules (Basel, Switzerland) · 2022Review
- Advances in PSMA theranostics.Translational oncology · 2022Article
- AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Relative Efficacy ofMolecular imaging and radionuclide therapy · 2022Article
- Translating a radiolabeled imaging agent to the clinic.Advanced drug delivery reviews · 2022Review
- Cold Kit Labeling: The Future ofFrontiers in medicine · 2022Review
- Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach.Molecules (Basel, Switzerland) · 2021Article
- Fifty Shades of Scandium: Comparative Study of PET Capabilities Using Sc-43 and Sc-44 with Respect to Conventional Clinical Radionuclides.Diagnostics (Basel, Switzerland) · 2021Article
- Advances in Development of Radiometal Labeled Amino Acid-Based Compounds for Cancer Imaging and Diagnostics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- A review of advances in the last decade on targeted cancer therapy usingAmerican journal of nuclear medicine and molecular imaging · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe AAZTA chelator and in particular its bifunctional derivative AAZTA
resultsAAZTA
conclusionsThe AAZTA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.